Intellia Therapeutics, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Intellia Therapeutics, Inc..The latest application filed is for "ionizable amine lipids".

Company Profile

25.0.37

Intellia Therapeutics, Inc. - Cambridge MA US
Intellia Therapeutics, Inc. -

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Ionizable Amine Lipids App 20220009878 - Parmar; Rubina Giare ; et al.	2022-01-13
Compositions and Methods for Immunotherapy App 20210340530 - Becker; Amy Melissa ; et al.	2021-11-04
Nucleic Acid Constructs And Methods Of Use App 20210316014 - Finn; Jonathan Douglas ; et al.	2021-10-14
Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing App 20210222173 - Dymek; Zachary William ; et al.	2021-07-22
Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1) App 20210163943 - Dymek; Zachary William ; et al.	2021-06-03
Compositions And Methods For Immunooncology App 20210123075 - CHEN; Ming-Wei ; et al.	2021-04-29
Modified Guide RNAs for Gene Editing App 20210087568 - Smith; Amy Madison Rhoden ; et al.	2021-03-25
Compositions And Methods For Immunooncology App 20210071182 - BROGDON; Jennifer ; et al.	2021-03-11
Polynucleotides, Compositions, and Methods for Genome Editing App 20200354702 - Dombrowski; Christian ; et al.	2020-11-12
In Vitro Method Of Mrna Delivery Using Lipid Nanoparticles App 20200308603 - Stewart; Morag H. ; et al.	2020-10-01
Compositions And Methods For Expressing Factor Ix App 20200289628 - Finn; John ; et al.	2020-09-17
Nucleic Acid Constructs And Methods Of Use App 20200268906 - Finn; John ; et al.	2020-08-27
Compositions And Methods For Treating Alpha-1 Antitrypsin Deficiency App 20200270618 - Finn; John ; et al.	2020-08-27
Compositions And Methods For Transgene Expression From An Albumin Locus App 20200270617 - Finn; John ; et al.	2020-08-27
Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis App 20200248180 - Kind Code	2020-08-06
Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) App 20200172564 - Dombrowski; Christian	2020-06-04
Methods For The Treatment Of Disease With Gene Editing Systems App 20200140896A1 -	2020-05-07
Methods And Compositions For Ocular Cell Therapy App 20200131474A1 -	2020-04-30
Compositions And Methods For The Treatment Of Hemoglobinopathies App 20200102561 - MICKANIN; Craig Stephen ; et al.	2020-04-02
Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency App 20190316129 - Odate; Shobu ; et al.	2019-10-17
Modified Guide RNAs App 20190316121 - Smith; Amy Madison Rhoden ; et al.	2019-10-17
Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four App 20190142972 - Burns; Sean Michael ; et al.	2019-05-16
Lipid Nanoparticle Formulations For Crispr/cas Components App 20190136231 - MORRISSEY; David V. ; et al.	2019-05-09
Compositions And Methods For The Treatment Of Hemoglobinopathies App 20190010495 - BOITANO; Anthony Edward ; et al.	2019-01-10
Compositions And Methods For Immunooncology App 20180362975 - CHEN; Ming-Wei ; et al.	2018-12-20
Methods And Compositions For Gene Editing App 20180112234 - Dombrowski; Christian ; et al.	2018-04-26
Methods And Compositions For Gene Editing App 20170260547 - Dombrowski; Christian ; et al.	2017-09-14

Company Registrations

SEC

0001652130

Intellia Therapeutics, Inc. of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.